Madaus, Europe’s leading supplier of natural pharmaceuticals and nutraceuticals, has named James H. Bruce as president and CEO of its North American subsidiary, Madaus, Inc.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Bruce will be responsible for developing and implementing a strategic plan to establish Madaus as a significant part of the US natural healthcare industry. He will direct all market development activities in health food, mass market, physician, and pharmaceutical sectors as well as explore growth opportunities through business alliances and acquisitions. Madaus had a 50% interest in Nature’s Way which it sold to Schwabe last year.
Founded in 1919 by three Madaus brothers, with the aim of developing, manufacturing, and distributing pharmaceuticals from medicinal plants, the privately held German company works under the “Nature & Science” theme to develop methodologies and rational science to introduce plant products into the European pharmaceutical market.
Prior to joining Madaus, Inc., Bruce was President & CEO of CV Technologies, a natural drug discovery company with primary offices in Boulder, Colorado, Edmonton, Alberta and Hong Kong. CVT holds over 25 composition and use patents for natural substances and is publicly traded on the Canadian Venture Exchange. From 1993 through 1998, Bruce was a senior executive with Amrion, Inc. in Boulder, Colorado. He served as Amrion’s VP of Sales and Marketing as well as President and CEO of Natrix International, Amrion’s Joint Venture with
Indena, SPA of Milan, Italy. He was also responsible for M&A and negotiated the purchase of Australian Natural Care of Sydney for Amrion. In 1998 Amrion was acquired by Whole Foods Markets.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
